Zai Lab (NASDAQ:ZLAB) Issues Quarterly Earnings Results, Beats Expectations By $0.18 EPS

Zai Lab (NASDAQ:ZLAB) issued its quarterly earnings results on Thursday. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.18, FiscalAI reports. The firm had revenue of $106.31 million during the quarter, compared to the consensus estimate of $103.87 million. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%.

Here are the key takeaways from Zai Lab’s conference call:

• Positive Sentiment: Zai Lab reported second-quarter net product revenue of $105.8 million, up 11% sequentially, while maintaining a commercially profitable business. Management expects KarXT, potential NRDL inclusions, and continued demand for key brands to support meaningful growth in 2027.
• Positive Sentiment: The DLL3 ADC zoci is advancing rapidly, with a global Phase III second-line small-cell lung cancer trial expected to complete enrollment in the first half of 2027 and a potential U.S. accelerated-approval submission later that year. The company also plans a first-line, chemo-sparing Phase III combination study and expects three registrational programs by year-end.
• Positive Sentiment: ZL-1503, a long-acting IL-13/IL-31 bispecific for atopic dermatitis, is expected to generate initial human pharmacokinetic, pharmacodynamic, safety, and immunogenicity data in the second half of 2026. Zai believes its potential for durable itch reduction, skin clearance, and less frequent dosing could differentiate it in a competitive market.
• Negative Sentiment: Management did not reaffirm its prior goal of reaching overall profitability by the end of 2025, instead indicating that profitability will develop over time as revenue grows and global assets advance. Continued investment in multiple global programs means operating expenses are expected to remain broadly stable through the rest of 2026.
• Neutral Sentiment: The company ended the quarter with $717.5 million in cash and is prioritizing spending on its highest-value programs while streamlining operations and expanding AI use across functions. Additional pipeline catalysts include initial ZL-6201 data expected in the first half of 2027 and an IND filing for the MUC17 T-cell engager ZL-1311 by year-end.

Zai Lab Price Performance

Zai Lab stock traded up $2.51 during mid-day trading on Thursday, hitting $20.88. The company’s stock had a trading volume of 1,388,022 shares, compared to its average volume of 799,173. The business has a 50 day moving average price of $18.59 and a 200-day moving average price of $19.20. Zai Lab has a 12 month low of $15.96 and a 12 month high of $36.77. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -12.89 and a beta of 0.78.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ZLAB. Citigroup dropped their price target on Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Weiss Ratings raised Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Zacks Research upgraded Zai Lab from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Wall Street Zen lowered Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Zai Lab presently has an average rating of “Moderate Buy” and an average price target of $40.00.

Insider Activity

In other news, CFO Yajing Chen sold 2,264 shares of Zai Lab stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $17.46, for a total value of $39,529.44. Following the transaction, the chief financial officer owned 35,691 shares in the company, valued at approximately $623,164.86. The trade was a 5.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ying Du sold 50,000 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $20.09, for a total value of $1,004,500.00. Following the completion of the sale, the chief executive officer directly owned 1,122,626 shares of the company’s stock, valued at approximately $22,553,556.34. This trade represents a 4.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 90,873 shares of company stock valued at $1,730,096. 4.88% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zai Lab

A hedge fund recently raised its position in Zai Lab stock. Royal Bank of Canada boosted its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 at the end of the most recent reporting period. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.